A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk

Ruth C Travis, Paul N. Appleby, Richard M Martin, Jeff M.P. Holly, Demetrius Albanes, Amanda Black, H Bas Bueno de Mesquita, June M. Chan, Chu-Chih Chen, Maria-Dolores Chirlaque, Michael B. Cook, Mélanie Deschasaux, Jenny L. Donovan, Luigi Ferrucci, Pilar Galan, Graham G. Giles, Edward L. Giovannucci, Marc J. Gunter, Laurel A. Habel, Freddie C HamdyKathy J. Helzlsouer, Serge Hercberg, Robert N Hoover, Joseph A.M.J.L. Janssen, Rudolf J Kaaks, Tatsuhiko Kubo, Loic Le Marchand, E. Jeffrey Metter, Kazuya Mikami, Joan K. Morris, David E. Neal, Marian L. Neuhouser, Kotaro Ozasa, Domenico Palli, Elizabeth A. Platz, Michael N. Pollak, Alison J. Price, Monique J. Roobol, Catherine Schaefer, Jeannette M. Schenk, Gianluca Severi, Meir Jonathan Stampfer, Pär Stattin, Akiko Tamakoshi, Catherine M. Tangen, Mathilde Touvier, Nicholas J. Wald, Noel S. Weiss, Regina G Ziegler, Timothy J Key, Naomi E. Allen, on behalf of the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group

Research output: Contribution to journalArticleResearchpeer-review

107 Citations (Scopus)


The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.

Original languageEnglish
Pages (from-to)2288-2300
Number of pages13
JournalCancer Research
Issue number8
Publication statusPublished - 15 Apr 2016
Externally publishedYes

Cite this